Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis

Metastasis of breast cancer occurs primarily through the lymphatic system, and the extent of lymph node involvement is a key prognostic factor for the disease. Whereas the significance of angiogenesis for tumor progression has been well documented, the ability of tumor cells to induce the growth of lymphatic vessels (lymphangiogenesis) and the presence of intratumoral lymphatic vessels have been controversial. Using a novel marker for lymphatic endothelium, LYVE-1, we demonstrate here the occurrence of intratumoral lymphangiogenesis within human breast cancers after orthotopic transplantation onto nude mice. Vascular endothelial growth factor (VEGF)-C overexpression in breast cancer cells potently increased intratumoral lymphangiogenesis, resulting in significantly enhanced metastasis to regional lymph nodes and to lungs. The degree of tumor lymphangiogenesis was highly correlated with the extent of lymph node and lung metastases. These results establish the occurrence and biological significance of intratumoral lymphangiogenesis in breast cancer and identify VEGF-C as a molecular link between tumor lymphangiogenesis and metastasis.

[1]  K. Alitalo,et al.  Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis , 1999, British Journal of Cancer.

[2]  E. Tschachler,et al.  Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. , 1998, Cancer research.

[3]  J. Price,et al.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. , 1990, Cancer research.

[4]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[5]  L. Leak.  Electron microscopic observations on lymphatic capillaries and the structural components of the connective tissue-lymph interface. , 1970, Microvascular research.

[6]  A. Eggert,et al.  High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  S. Hirohashi,et al.  Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[10]  K. Alitalo,et al.  VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. , 1997, Developmental biology.

[11]  J. Plouet.  [Angiogenesis and tumor growth. Angiogenic factors and tumor growth]. , 1999, Annales de pathologie.

[12]  R. Gilchrist,et al.  Surgical management of advanced cancer of the breast. , 1950, A.M.A. archives of surgery.

[13]  I. Zeidman.  Experimental studies on the spread of cancer in the lymphatic system. III. Tumor emboli in thoracic duct; the pathogenesis of Virchow's node. , 1955, Cancer research.

[14]  M. Skobe,et al.  Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. , 2000, The American journal of pathology.

[15]  K. Alitalo,et al.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. , 1998, The American journal of pathology.

[16]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. , 1990, Microvascular research.

[18]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[19]  Mihaela Skobe,et al.  Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.

[20]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[21]  T. Obara,et al.  Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. , 1999, Surgery.

[22]  J. M. Yoffey.  The regeneration of lymphatics. , 1953, Journal international de chirurgie.

[23]  L. Mariani,et al.  Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. , 1999, The American journal of pathology.

[24]  J. Vaillant,et al.  Vegf, vegf‐B, vegf‐C and their receptors KDR, FLT‐1 and FLT‐4 during the neoplastic progression of human colonic mucosa , 2000, International journal of cancer.

[25]  R. Tilghman,et al.  LYMPH VESSELS IN RABBIT CARCINOMA: WITH A NOTE ON THE NORMAL LYMPH VESSEL STRUCTURE OF THE TESTIS , 1933 .

[26]  M. Skobe,et al.  Structure, function, and molecular control of the skin lymphatic system. , 2000, The journal of investigative dermatology. Symposium proceedings.

[27]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[28]  M. Witte,et al.  Lymphangiogenesis: mechanisms, significance and clinical implications. , 1997, EXS.

[29]  B. Copeland,et al.  Experimental studies on the spread of cancer in the lymphatic system. II. Absence of a lymphatic supply in carcinoma , 1955, Cancer.

[30]  J. Kurebayashi,et al.  Expression of Vascular Endothelial Growth Factor (VEGF) Family Members in Breast Cancer , 1999, Japanese journal of cancer research : Gann.

[31]  Y. Maehara,et al.  Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues , 2000, British Journal of Cancer.

[32]  D. Birnbaum,et al.  VEGFc and VEGFR3 expression in human thyroid pathologies , 2000, International journal of cancer.

[33]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[34]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. , 1991 .

[35]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Yihai Cao,et al.  Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.

[37]  D. Jackson,et al.  LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan , 1999, The Journal of cell biology.

[38]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[39]  M. Oda,et al.  Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. , 2000, The Journal of thoracic and cardiovascular surgery.

[40]  R. K. Bright,et al.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.

[41]  H. Florey,et al.  Some Observations on the Structure and Functions of Lymphatics: Their Behaviour in Local Œdema , 1935 .

[42]  Takuma Sasaki,et al.  Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  Benoit Vf.  Clinical problem-solving: if at first you don't succeed. , 1996 .